SS-31

ʻO SS-31 kahi peptide liʻiliʻi-mole me ʻehā amino acids; e kuhikuhi pono ana i ka mitochondria.

Pane wikiwiki

SS-31 (Elamipretide) is a mitochondria-targeted antioxidant peptide that precisely scavenges intracellular reactive oxygen species. It protects cellular mitochondrial structure and function, ideal for oxidative aging and cell metabolism laboratory research.

SKU: 198887 Māhele:
Kaʻana like i kāu aloha

SS-31 (elamipretide) he peptide liʻiliʻi-mole me ʻehā nā ʻakika amino; kikoʻī kikoʻī mitochondria.

Ke komo pono o nā membrane cell ʻo ia kekahi o kāna mau hiʻohiʻona nui, me ka pahu hopu pololei o ka membrane mitochondrial i loko.

ʻAʻole hiki i nā antioxidants kuʻuna ke hōʻiliʻili pono i loko o ka mea paʻa matrix mitochondrial, hoʻomākaʻi ʻana ʻano oxygen reactive (ROS) ma ke ano he kaohi nui.

ʻO ka hoʻolālā kūʻokoʻa o SS-31 e ʻae i ka neutralization o nā radical manuahi, a me nā ʻano like ʻole nā pilina electrostatic/nā pilina hydrophobic; ʻO ka heleuma kikoʻī i ka mitochondria iā ia iho he hopena pololei o kēia.

ʻIke ʻia ka lāʻau lapaʻau Mitochondrial holoʻokoʻa i ka SS-31 ʻo ia kekahi o nā lāʻau lapaʻau kokoke loa e hiki mai ana..

Ma waho aʻe o nā hopena cytoprotective, ʻike ʻia nā hana hoʻoponopono ikaika.

ʻO ka uhaki ʻana i ka pōʻai ʻino ʻino mua o ke koʻikoʻi oxidative ka mea e hoʻokaʻawale ai iā SS-31.

Hoʻomaikaʻi i ka myocardial ikehu metabolism, liʻiliʻi liʻiliʻi infarct nui, ka hana puʻuwai holoʻokoʻa, a i kekahi manawa, hana neurodegenerative, hiki i na mea a pau.

ʻO ka hoʻomanawanui hoʻoikaika kino a me ka ikaika o ka ʻiʻo, he mea nui nae, nā hopena i hiki iā SS-31 ke hoʻoikaika.

Kaʻina

D-Arg-Dmt-Lys-Phe-NH2; Dmt=2',6'-dimethylTyr

Helu CAS

736992-21-5

ʻĀpana Molekala

C32H49N9O5

Kaumaha Molekala

639.8 g/mol

Imi No SS-31

1.Nā noi lāʻau lapaʻau a me ka hiki ke hoʻōla

Ua hōʻike nā hoʻokolohua lapaʻau mua i nā hopena cytoprotective koʻikoʻi – nā myopathies mitochondrial mua, ʻO Barth syndrome, puʻuwai hāʻule, ʻeha ʻeha ʻeha a me ka ma'i maka malo'o e hō'ike ana i nā wahi maika'i o ka ho'ohana 'ana i ka lā'au lapa'au.

2.Nā hopena antioxidant

Hoʻolaha nui ʻia nā antioxidants maʻamau akā e like me ka mea i ʻōlelo ʻia ma luna nei, ʻaʻole i komo i loko.

Hiki i nā waiwai physicochemical o SS-31 ke hiki i ka hōʻiliʻili koho nui.

ʻO ka hāʻawi electron (dimethyltyrosine) pili pono a hoʻopau i nā radical manuahi i hana ʻia i loko o ka kaulahao lawe electron.

ʻO ka hoʻopau ʻana i ka pae kumu o ke koʻikoʻi oxidative ka pahuhopu kumu; palekana o DNA mitochondrial, mau (maikaʻi loa) mālama i ka microenvironment, a me ka mea nui, hana ikehu ola, ʻo ia ka hopena o nā mea a pau i luna.

Hoʻolohi a hoʻopaneʻe paha i nā kaʻina hana ʻelemakule a me kahi ākea o nā maʻi hiki ʻole ke hoʻōla ʻia ma mua, ʻo ia nā pahuhopu hope o kēia laina noiʻi.

3.Hoʻomaikaʻi i ke kūlana ikehu ʻōnaehana i hoʻopilikia ʻia e ka maʻi kanesa a me ka chemotherapy

I ka ʻiʻo iwi o nā maʻi maʻi maʻi, ʻO ka mitochondrial dysfunction ke kumu nui o ka emi ʻana Hoʻohui ATP; ʻO ka atrophy ʻiʻo hiki ʻole ke hoʻololi ʻia a me ka deformation ma hope mai e like me ka hopena pololei.

Hoʻopau maikaʻi ʻo SS-31 cachexia, pale i ka hōʻemi ʻana i ka wahi o ka fiber muscle glycolytic, poloka i ka poho mitochondrial a me nā ʻano like ʻole autophagy/mitosis.

ʻIkepili o ka ʻiʻo iwi, ate, a me nā metabolites plasma e hōʻike ana i nā loli nui i ka ikehu a me ka protein metabolism i loko o ka pūʻali maʻi tumora.

4.Ka hoʻomaikaʻi ʻana i ka mitochondrial dysfunction a me ka hōʻino hoʻomanaʻo pili

Endotoxin-Hōʻike nā ʻiole i mālama ʻia i nā ʻano āpau o kēia dysfunction mitochondrial – kaumaha oxidative, nā pane inflammatory, apoptosis neuronal, kuamoʻo dendritic hippocampal poho – ke aʻo a me nā mana hoʻomanaʻo maʻalahi e like me ka hopena.

Hōʻike nā hoʻokolohua i nā hopena pale o SS-31 i nā mea i haʻi mua ʻia; modulation o ʻO ke kumu neurotrophic no ka lolo, aiʻole aneurin BDNF hōʻailona ma ke ʻano he ala kī.

ʻO ka hoʻihoʻi ʻana o kekahi mau hoʻololi protein hōʻailona synaptic a hoʻonui (physiological) ʻike ʻia ka paʻakikī o nā synapses.

Hiki i ka lāʻau lapaʻau no ke kaumaha oxidative/neuroinflammation ʻike ʻia ke ʻano pōʻino.

5.Kāohi i ka mitochondrial permeability transition pore (mPTP) wehe ʻia e pale i ka apoptosis

Mālama ʻo SS-31 i ka pono o ka membrane mitochondrial i loko, ma o nā hopena antioxidant a me nā hopena synthesis ATP paʻa.

Hana pololei ma adenine nucleotide translocator (ANT) hoʻokuke i ka paepae no mitochondrial permeability transition pore /mPTP wehe ana.

Hoʻopau maikaʻi ʻia ka hoʻōla mua ʻana o kēia kaʻina hana; nā kūlana koʻikoʻi (hōʻeha o ka myocardial, hahau e like me na hihia hoike) hiki ke mālama ʻia ma ka liʻiliʻi loa e kēia laina o ka inhibition.

6.Kāohi ʻana i kahi pane ʻāhu

Hoʻopili ʻia nā mea a pau i luna.

Hoʻomaikaʻi ʻia ka hana Mitochondrial, hoemiia ka poino, a ʻo nā hopena a pau o lalo o ka ʻaʻa maʻi a i ʻole ka maʻi ʻeha e hoʻemi iki ʻia.

Aia ka waiwai therapeutic piha o SS-31 i kēia mau hui, nae kumu, nā hana anti-inflammatory.

COA

HPLC

MS

(1)Ballaro, R.; Lopalco, P.; Audrito, V.; Beltra, M.; Pin, F.; ʻO Angelini, R.; iwi aoao, P.; Lio, A.; Bonetto, A.; Szeto, H. H.; et al. ʻO ka huli ʻana i ka Mitochondria e SS-31 e hoʻomaikaʻi i ke kūlana o ke kino holoʻokoʻa i ka maʻi maʻi- a me Chemotherapy-Induced Cachexia. Nā maʻi maʻi maʻi (Basel) 2021, 13(4). DOI: 10.3390/ma'i 'a'ai13040850 Mai NLM PubMed-not-MEDLINE.

(2)Cai, J.; ʻO Jiang, Y.; ʻO Zhang, M.; ʻO Zhao, H.; Li, H.; Li, K.; ʻO Zhang, X.; Qiao, Ua ʻōlelo ʻo T. Nā hopena pale o ka mitochondrion-targeted peptide SS-31 e kūʻē i ka ʻeha hope o ka ischemia-reperfusion.. J Physiol Biochem 2018, 74(2), 335-343. DOI: 10.1007/s13105-018-0617-1 Mai NLM Medline.

(3)ʻO Dai, ʻO D. F.; ʻO Chen, Ua ʻōlelo ʻo T.; Szeto, H.; Nieves-Cintron, M.; waina ʻīlio, V.; Santana, L. F.; Rabinovitch, P. S. ʻO ka Peptide antioxidant i manaʻo ʻia ʻo Mitochondrial e hoʻomaikaʻi i ka maʻi hypertensive cardiomyopathy. J Am Coll Cardiol 2011, 58(1), 73-82. DOI: 10.1016/j.jacc.2010.12.044 Mai NLM Medline.

(4)ʻO Ding, X. Ua ʻōlelo ʻo W.; Robinson, M.; Li, R.; Aldhowayan, H.; ʻO Geetha, Ua ʻōlelo ʻo T.; Babu, J. R. Mitochondrial dysfunction a me nā hopena maikaʻi o ka mitochondria-targeted peptide liʻiliʻi SS-31 i ka Diabetes Mellitus a me ka maʻi o Alzheimer.. ʻO Pharmacol Res 2021, 171, 105783. DOI: 10.1016/j.phrs.2021.105783 Mai NLM Medline.

(5)Nā waina ʻono, M. Ua ʻōlelo ʻo T.; Pipipin, J. Ua ʻōlelo ʻo W.; Ua haʻi aku ʻo Eng, ʻO D. ʻO G.; Hudkins, K. L.; ʻO Chiao, Y. A.; Campbell, M. D.; na Marcin, ʻO D. J.; Alpers, C. E.; Szeto, H. H.; Rabinovitch, P. S.; Shankland, S. J. ʻO ka peptide i hoʻopaʻa ʻia i ka mitochondrial, SS-31, hoʻomaikaʻi i ka hoʻolālā glomerular i nā ʻiole o ka wā kahiko. Kidney Int 2017, 91(5), 1126-1145. DOI: 10.1016/j.kint.2016.10.036 Mai NLM Medline.

(6)Szeto, H.; ʻO Zhang, Y.; Nakagawa, Y.; lāʻau ʻoka, C.; ʻōmaʻomaʻo, S.; Ua ʻōlelo ʻo Deng, X.; Rodeo, S.; ʻO Zhang, X. ʻO ka loiloi o SS-31 ma ke ʻano he Potential Therapeutic Target i ka mālama ʻana o Tendinopathy. Orthopedic Journal of Sports Medicine 2020, 8(7_suppl6). DOI: 10.1177/2325967120s00395.

(7)ʻO Zhang, H.; ʻO Chen, Y.; Li, F.; ʻO Wu, C.; Cai, Ua ʻōlelo ʻo W.; ʻAe, H.; ʻo lākou, H.; He, M.; ʻO ka mea, L.; ʻO Wang, X.; et al. Hoʻopau ʻo Elamipretide i ka pyroptosis i loko o ke kuamoʻo ʻeha i hōʻeha ʻia ma ke kāohi ʻana i ka cPLA2-induced lysosomal membrane permeabilization. J Neuroinflammation 2023, 20(1), 6. DOI: 10.1186/s12974-023-02690-4 Mai NLM Medline.

(8)ʻO Zhao, Ua ʻōlelo ʻo W.; ʻO Xu, Z.; Kao, J.; Fu, Q.; ʻO Wu, Y.; ʻO Zhang, X.; lōʻihi, Y.; ʻO Zhang, X.; ʻO ka mea, Y.; Li, Y.; Ua haʻi aku ʻo Mi, Ua ʻōlelo ʻo W. Elamipretide (SS-31) hoʻomaikaʻi i ka hana mitochondrial, synaptic a me ka hoʻomanaʻo impairment i hoʻokomoʻia e ka lipopolysaccharide i nāʻiole. J Neuroinflammation 2019, 16(1), 230. DOI: 10.1186/s12974-019-1627-9 Mai NLM Medline.

Kaʻina:

D-Arg-Dmt-Lys-Phe-NH2; Dmt=2',6'-dimethylTyr

CAS:

736992-21-5

M.W:

639.8 g/mol

Home Huli Whatsapp Nā lawelawe Huahana